Počet záznamů: 1
Immunotherapy of MHC class I-deficient tumors
- 1.
SYSNO ASEP 0352661 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Immunotherapy of MHC class I-deficient tumors Tvůrce(i) Reiniš, Milan (UMG-J) RID Zdroj.dok. Future Oncology - ISSN 1479-6694
Roč. 6, č. 10 (2010), s. 1577-1589Poč.str. 13 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova tumor vaccine ; MHC class I expression ; antigen presenting machinery Vědní obor RIV EB - Genetika a molekulární biologie CEP GA301/07/1410 GA ČR - Grantová agentura ČR GAP301/10/2174 GA ČR - Grantová agentura ČR IAA500520807 GA AV ČR - Akademie věd IAA500520605 GA AV ČR - Akademie věd CEZ AV0Z50520514 - UMG-J (2005-2011) UT WOS 000284192800011 DOI 10.2217/FON.10.128 Anotace MHC class I downregulation is a general mechanism by which tumor cells can escape from T-cell-mediated immunity. Therefore, successful imunotherapeutic and vaccination protocols should be optimized against tumors with distinct cell surface expression of the MHC class I molecules. Mechanisms leading to protective immunity may vary in different models with respect to the particular tumors, e.g. to their levels of residual expression of the MHC class I molecules on tumor cells or inducibility of MHC class I expression. Notably, both CD8+ cell-mediated immunity and MHC class I-unrestricted mechanisms can take place against MHC class I-deficient tumors. Since MHC class I downregulation is frequently reversible by cytokines and also by activation of epigenetically silenced genes, an attractive strategy is to elicit specific cell-mediated immunity combined with restoration of MHC class I expression on tumor cells. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2011
Počet záznamů: 1